The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Neomile Growth Fund Series 1
AHCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Neomile Growth Fund-Series I (along with PAC Neomile Corporate Advisory Limited), a non-promoter entity, sold 14,75,992 shares (2.78% of equity) of Anlon Healthcare Ltd through open market between 3rd and 4th November 2025. Their holding reduced from 55,28,667 shares (10.40%) to 40,52,675 shares (7.62%). The sale was executed via open market, and the seller clarified it does not belong to the promoter/promoter group. Anlon Healthcare's total equity share capital stands at 5,31,51,500 shares.
A non-promoter fund trimming a 2.78% block via open market could create short-term selling pressure on Anlon Healthcare shares. The fund still holds 7.62%, keeping it above the 5% major-shareholder disclosure threshold, so further sales may attract regulatory attention.